Primary adrenal lymphoma (PAL) is extremely rare although involvement of malignant lymphoma into adrenals is common. We report a case of a 58-year-old man with bilateral PAL who demonstrated adrenal insufficiency. Primary large B-cell lymphoma was proven by a computed tomography-guided needle biopsy of the adrenal tumor. Although a complete remission was once achieved by combination chemotherapy plus rituximab, a recurrence occurred with brain metastasis leading to his death. We concluded that PAL should be considered as a possible cause of bilateral adrenal incidentalomas with progressive adrenal insufficiency.
Introduction
Primary extranodal lymphomas accounts for approximately one-third of all lymphomas and could occur in any body organ. However, non-Hodgkin lymphoma (NHL) arising in the endocrine system represents only 3% of extranodal malignant lymphomas, and is usually confined to the thyroid gland (1) . The adrenal gland is a frequent site of neoplastic disease. Therefore, it is important to perform differential diagnosis for the adrenal tumor. Primary adrenal lymphoma (PAL) is an extremely rare entity. Some patients with bilateral PAL (bPAL) show clinical or laboratory signs of adrenal insufficiency, which are not usually seen in unilateral adrenal NHL. Here, we report a case of bilateral adrenal tumor presenting adrenal failure. The tumor was found to be a diffuse large B-cell lymphoma by computed tomography (CT)-guided needle biopsy.
Case Report
A 58-year-old man was referred and admitted to our department for further examination of bilateral 10 cm adrenal mass lesions. In November 2003 (thirteen months before admission), he was diagnosed as anemia and liver dysfunction on routine check-up. In January 2004 (one month before admission), he presented nocturnal sweating and back pain and visited another hospital. Even though no abnormal findings were observed by gastroduodenal endoscopy or total colonoscopy, abdominal CT revealed bilateral 10 cm adrenal mass lesions.
In February 2004, he was referred to the urology department in our hospital for an operation to remove the tumors. However, he complained of general fatigue and appetite loss. Moreover, he presented with fever of unknown origin and frequent hypoglycemia. Based on the symptoms above and bilateral adrenal masses, adrenal insufficiency was suspected and he was referred to our department for further en- (Table 1) showed anemia (Hb 7.8 g/dL). Biochemical analysis revealed elevated levels of serum LDH, ALP, γ-GTP and transaminases. Hyponatremia, hyperkalemia and severe hypoglycemia were observed, suggesting adrenal insufficiency. Elevated levels of serum CRP, ESR, NSE, Pro-GRP and soluble interleukin-2 (IL-2) receptor (9,860 U/mL) were also noted. Plasma ACTH levels were high (101 pg/mL). Serum DHEA-S (292 ng/mL) and plasma aldosterone (32 pg/mL) levels were low. Rapid ACTH test (Table 2) showed no response in plasma cortisol levels revealing primary adrenal failure. Abdominal plain CT detected two masses both measuring 10 cm diameter in the adrenal glands with comparable and homogenous density (Fig. 1A) . Magnetic resonance imaging (MRI) also demonstrated bilateral adrenal masses in which the central high intensity in T2-weighted image indicated necrosis and/or hemorrhage (Fig. 1B, C) . Galium ( 67 Ga) scintigraphy revealed strong tracer uptake in the bilateral adrenal masses (Fig. 1D ). F-18 fluorodeoxy-glucose positron emission tomography (FDG-PET) demonstrated that there was strong uptake in the bilateral adrenal tumor and that the standard uptake value (SUV) was extremely high (SUV =8.8) (Fig. 1E) .
T a b l e 1 . L a b o r a t o r y Da t a o n Ad mi s s i o n t o Ou r De p a r t me n t
Based on the laboratory data and imaging analysis, adrenal lymphoma was highly suspected at this point. To make a definite diagnosis, CT-guided needle biopsy was performed. Pathological studies demonstrated diffuse infiltration of atypical lymphocytes replacing the normal adrenal structure in the specimen and the proliferation of atypical lymphocytes was not detected within the lumina of small vessels. Immunohistochemical study showed that B-lymphocytederived markers such as CD20 and CD79a were exclusively positive in large atypical lymphocytes in the specimen (Fig. 2) . Thus, we diagnosed that he suffered from diffuse large B-cell malignant lymphoma (DLBCL), which originated in the bilateral adrenal glands.
On admission, he developed anorexia, general fatigue and hypoglycemia followed by transient unconsciousness reflecting adrenal insufficiency. Hydrocortisone was administered intravenously (300 mg/day) and his symptom was markedly improved. Upon symptom improvement, 60 mg of hydrocortisone was administered orally. His clinical lymphoma stage was assessed as stage IV. His performance status was evaluated as level 3 (2) and he was at high intermediate risk according to international prognostic index (3). On the 30th day of admission, the full-dose CHOP therapy [cyclophosphamide (CPM) 1,300 mg, adriamycin (ADM) 87 mg, vincristine (VCR) 2.0 mg, prednisone (PSL) 100 mg for 5 days] was started. At the time of the first cycle of chemotherapy, we did not add rituximab (R) since we had not known that the lymphoma was positive for CD20. On the 49 th day of the admission, the second cycle of the CHOP therapy was performed. On the second cycle, we reduced the dosage of the CHOP therapy (CYP 1,220 mg, ADM 80 mg, VCR 2.0 mg, PSL 100 mg for 5 days) because of his weight loss by 10 kg after the first cycle of the treatment. We also added rituximab (610 mg) on the first day of the second cycle, because lymphoma cells were positive for CD 20 in immunohistological study. On the 61st day of the admission, the third cycle of CHOP (R-CHOP) therapy was
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performed. After the second cycle of CHOP therapy, the CT scan showed that the bilateral adrenal masses were clearly decreased in size demonstrating a response to the chemotherapy (Fig. 3) . Soluble IL-2 receptor levels were also decreased from 9,860 U/mL to 574 U/mL. After the third cycle of the chemotherapy, 30 mg of hydrocortisone was administered to maintain his adrenal function. The chemotherapy was performed in the department of hematology from the fourth cycle. The hematologist planed high dose chemotherapy with autologous stem cell transplantation support after the sixth cycle of the CHOP therapy, because he was evaluated as high intermediate risk group according to international prognostic index. On the 160th day of the admission, the patient developed consciousness loss and brain CT scan revealed that massive enhanced area surrounded by low-density area, indicating brain metastasis with edema in the left frontal lobe (Fig. 4A, B) . Whole brain radiation was performed upon diagnosis. The total radiation dose was 39 Gy. After the radiation, the metastatic brain tumor was diminished, however on the 224th day of the admission, the patient developed consciousness loss again due to recurrence of metastatic brain tumor. On the 226th day of the admission, a modified DHAP therapy (carboplatin 640 mg, cytarabine 6,400 mg, dexamethasone 160 mg) was performed but failed to induce any clinical improvement. He died of respiratory insufficiency on the 264th day of admission. Postmortem examination was performed under his family's agreement. Lymphoma cells developed mainly in the lateral cerebral ventricle and were also disseminated in the arachnoid membrane of the brain surface. Perivascular infiltration of lymphoma cells was notable indicating hematogenous metastasis. It was revealed that he died due to cerebellar tonsillar herniation due to tumor metastasis. The recurrent bilateral adrenal tumor was also observed. 
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Discussion PAL is a rare neoplastic disease with about 116 reports in the literature (4) . PAL represents only 3% of extranodal lymphomas (4) (5) (6) . Nearly 70% of PAL cases reveal bilateral adrenal involvement as in the present case (7, 8) . PAL (including both unilateral and bilateral) occurs with a male: female ratio of 3:1 and a median age of 68 years (4, (6) (7) (8) . We searched 60 cases of bilateral PAL (bPAL) in the literature through PubMed. According to our search for bPAL (Table 3), bPAL occurs with a male: female ratio of 1.6 : 1 and median age is 64.9 and 65.2 years for males and females, respectively. Therefore, no significant differences in sex and T a b l e 3 . Ca s e Re p o r t s o f B i l a t e r a l P r i ma r y Ad r e n a l L y mp h o ma , a s  S e a r c h age between whole and bilateral PAL were detected. Mean survival period of bPAL is 13.0 months. The overall survival time totally depends on the ability to establish proper diagnosis early in order to start adequate treatment as soon as possible. We should also keep in mind adrenocortical carcinomas and malignant pheochromocytomas for differential diagnosis of bilateral adrenal infiltrations, which could be a cause of delayed diagnosis for PAL. Bilateral enlargement of adrenal glands should raise the suspicion of lymphoma, especially in patients with clinical or laboratory features of adrenal insufficiency (9, 10) . In the current case, a CT-guided fine needle biopsy was performed. Percutaneous fine needle biopsy under CT or ultrasound guidance can only be recommended in cases of suspicious PAL (8, (11) (12) (13) (14) (15) (16) . The tumor was comprised of large cells, which were immunohistologically positive for CD20 and CD79a. Thus, the tumor was diagnosed as a DLBCL. In fact DLBCL is the most common histological diagnosis for bPAL (4, 12) . As a histological differential diagnosis, we should consider intravascular large B-cell lymphoma (IVL). IVL is classified as DLBCL subtype, according to the new WHO classification (17) . IVL is characterized by intravascular proliferation of malignant lymphomatous cells, which frequently invade the central nervous system (CNS), skin, lungs and kidneys (12, 18, 19) . Both pituitary and adrenal involvement are frequent in IVL patients (12, 20, 21) . Noteworthy is that CNS infiltration is described in 50% of Japanese patients with primary adrenal IVL (12) . It often takes an aggressive clinical course and it has been recently known that rituximab is effective for IVL. The Asian variant of intravascular lymphoma (AIVL), which is mainly seen in Asian countries and may be complicated by hemophagocytic syndrome, should also be considered as another differential diagnosis (18, 19, 22) . AIVL takes an exceedingly rapid clinical course as seen in IVL and (R)-CHOP is effective in some cases of AIVL. However, CNS involvement is rare in AIVL (19, 22) . The present case is similar to IVL in bilateral adrenal and CNS infiltration, however, histological study of adrenal masses revealed no evidence of IVL. Thus, we concluded that the current case is histologically diagnosed as primary adrenal DLBCL. In recent cases, (R)-CHOP has been the standard treatment as performed in this case (23) (24) (25) . A poor prognosis is thought to be due to advanced age at diagnosis, large tumor size, increased LDH levels, and adrenal insufficiency at the time of presentation, indicating extensive adrenal destruction (7). It is still controversial whether the total adrenorectomy should be done prior to chemotherapy and we did not choose an operation in the current case. The roles of radiation therapy and surgical excision of the adrenal glands in the context of bilateral involvement are not known (7, 26) . Even though bilateral adrenal masses were clearly decreased in size after the 6th cycle of R-CHOP therapy, the present case developed involvement of CNS and the clinical course progressed rapidly thereafter. In fact, the incidence of CNS involvement is determined by the extent and proliferation of PAL (27, 28) .
In conclusion, we reported a rare and important case of bilateral primary adrenal non-Hodgkin lymphoma presenting as adrenal failure. We suggest that PAL should be considered as a possible cause of bilateral adrenal incidentalomas with progressive adrenal insufficiency.
